Block on Trump's Asylum Ban Upheld by Supreme Court
The U.S. Food and Drug Administration (FDA) announced that it has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents aged 13 to 17, and for short-term treatment of certain types of bipolar disorder in children and adolescents aged 10 to 17. This is the first FDA approval of an atypical antipsychotic drug to treat either disorder in these age groups. In April 2005, FDA issued an alert informing patients of the risks associated with Risperdal use, including stroke, nervous system and movement problems, high blood sugar, and diabetes.
Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.
Sign into your Legal Forms and Services account to manage your estate planning documents.Sign In
Create an account allows to take advantage of these benefits: